Mobile devices to detect early pneumonitis in stage III NSCLC patients on durvalumab.

Trial Identifier: D4194C00008
Sponsor: AstraZeneca
NCTID:: NCT04381494
Start Date: April 2020
Primary Completion Date: January 2022
Study Completion Date: January 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation

Trial Locations

Country Location
US, CA Long Beach, CA, US, 90806
US, CA Santa Ana, CA, US, 92705
US, CO Englewood, CO, US, 80113
US, CT Plainville, CT, US, 06062
US, FL Boca Raton, FL, US, 33486
US, FL Tallahassee, FL, US, 32308
US, FL Tampa, FL, US, 33612
US, GA Atlanta, GA, US, 30322
US, KS Westwood, KS, US, 66205
US, KY Louisville, KY, US, 40241
US, MA Worcester, MA, US, 01655
US, MI Pontiac, MI, US, 48341
US, MN Rochester, MN, US, 55905
US, NE Omaha, NE, US, 68114
US, NV Reno, NV, US, 89502
US, NY New York, NY, US, 10029
US, OH Cincinnati, OH, US, 45267
US, OH Massillon, OH, US, 44646
US, PA Fountain Hill, PA, US, 18015
US, TN Knoxville, TN, US, 37916
US, TX Austin, TX, US, 78705
US, TX Dallas, TX, US, 75203
US, TX Harlingen, TX, US, 78550
US, TX San Antonio, TX, US, 78229
US, VA Fairfax, VA, US, 22031
US, WA Lacey, WA, US, 98503
US, WA Tacoma, WA, US, 98405